Strengthening Group Management and the Laboratory Network
First written in FY2016. 8 of 13 entries say "Advanced", first in FY2017. Latest entry: FY2026-H1.
25 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「Ceased to exist following its absorption in a merger by the company: ㈱BMLライフサイエンス・ホールディングス (excluded from consolidated subsidiaries)」
Effective 1 September 2025, the company absorbed BMLライフサイエンス・ホールディングス in a merger and excluded it from the scope of consolidation. - FY2025-H1AdvancedAnnual report
「Ceased to exist following its absorption in a merger by QCL, a consolidated subsidiary of the company (formerly ㈱QOLセントラルラボラトリーズ): ㈱協同医学研究所 (excluded from consolidated subsidiaries) ㈱リンテック (excluded from consolidated subsidiaries)」
Effective 1 August 2024, QCL, the surviving company, absorbed 協同医学研究所 and LINTEC Corporation in a merger, and both companies were excluded from the scope of consolidation. - FY2024-Q3RestatedAnnual report
「Ceased to exist following its absorption in a merger by the company: ㈱愛媛メディカルラボラトリー (excluded from consolidated subsidiaries)」
The exclusion of 愛媛メディカルラボラトリー from the consolidated subsidiaries following its absorption in a merger is restated as a change involving a major affiliated company. - FY2024-Q2AdvancedAnnual report
「Ceased to exist following its absorption in a merger by the company: ㈱愛媛メディカルラボラトリー (excluded from consolidated subsidiaries)」
As part of the group reorganization, the company absorbed its former consolidated subsidiary 愛媛メディカルラボラトリー in a merger and excluded it from the scope of consolidation. - FY2023-Q3RestatedAnnual report
「Ceased to exist following its absorption in a merger by the company: ㈱東京公衆衛生研究所 (excluded from consolidated subsidiaries)」
The exclusion of 東京公衆衛生研究所 from the consolidated subsidiaries following its absorption in a merger is restated as a change involving a major affiliated company. - FY2023-Q2RestatedAnnual report
「Ceased to exist following its absorption in a merger by the company: ㈱東京公衆衛生研究所 (excluded from consolidated subsidiaries)」
The exclusion of 東京公衆衛生研究所 from the scope of consolidation following its absorption in a merger is restated as a change involving an affiliated company. - FY2023-Q1RestatedAnnual report
「Ceased to exist following its absorption in a merger by the company: ㈱東京公衆衛生研究所 (excluded from consolidated subsidiaries)」
The exclusion of 東京公衆衛生研究所 from the scope of consolidation following its absorption in a merger is restated as a change involving a major affiliated company. - FY2022AdvancedAnnual report
「㈱東京公衆衛生研究所 was absorbed in a merger by the company effective 1 April 2022.」
As part of the group reorganization, the company absorbed 東京公衆衛生研究所 in a merger effective 1 April 2022. The restructuring of BML総合研究所 based on the Eighth Medium-Term Management Plan is also planned. - FY2022-Q1AdvancedAnnual report
「Ceased to exist following its absorption in a merger by the company: ㈲ＴＭＳ (excluded from non-consolidated subsidiaries)」
As part of the group reorganization, the company absorbed its former non-consolidated subsidiary 有限会社TMS in a merger, changing the composition of its affiliated companies. - FY2020-Q3AdvancedAnnual report
「During the third quarter of the current consolidated fiscal year, ㈱第一臨床医学検査センター, which had been a consolidated subsidiary, was absorbed in a merger with the company and ceased to exist as the absorbed company. It has therefore been excluded from the scope of consolidation.」
As part of the group reorganization, the company absorbed its consolidated subsidiary 第一臨床医学検査センター in a merger and excluded it from the scope of consolidation. - FY2020-Q1AdvancedAnnual report
「As part of our group strategy, we acquired shares in ㈱東海細胞研究所 and made the company a consolidated subsidiary from the current fiscal year.」
Describes specific progress under the group strategy, namely the acquisition of all shares in 東海細胞研究所 and its conversion into a consolidated subsidiary from the current fiscal year. - FY2017AdvancedAnnual report
「To ensure the proper conduct of operations at affiliated companies, we have established the Regulations for Management of Affiliated Companies, which sets out general management policies and the management structure, and are working to ensure its proper implementation for smooth operations. We also hold meetings of affiliated companies regularly and use them as forums for exchanging information. In accordance with our internal rules, we are establishing compliance and risk management systems across the group as an integrated corporate group.」
Specifically describes the establishment of the Regulations for Management of Affiliated Companies, regular meetings of affiliated companies, and group-wide compliance and risk management systems. - FY2016First statedAnnual report
「We will continue to strengthen group management and expand synergies by reorganizing the laboratory network, integrating operations including sales and collection and delivery, centralizing asset and procurement management, and promoting personnel exchanges among group companies.」
Lists laboratory reorganization, operational integration, centralized management, and personnel exchanges as means of expanding group synergies.